Screener
Veracyte VCYT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (319) | (577) |
| Accounts payable | 2,587 | 7,120 |
| Accrued liabilities and deferred revenue | (6,120) | (8,889) |
| Net cash provided by operating activities | 35,215 | 5,362 |
| Investing activities | ||
| Purchase of short-term investments | (124,999) | (49,999) |
| Purchases of property, plant and equipment | (2,962) | (1,819) |
| Net cash used in investing activities | (127,961) | (51,818) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's operating cash flow?
- Veracyte (VCYT) reported operating cash flow of $35.22M in Q1 2026.
- How has Veracyte's operating cash flow changed year-over-year?
- Veracyte's operating cash flow increased by 556.8% year-over-year, from $5.36M to $35.22M.
- What is the long-term trend for Veracyte's operating cash flow?
- Over 3 years (2022 to 2025), Veracyte's operating cash flow has grown at a 162.5% compound annual growth rate (CAGR), from $7.54M to $136.31M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Veracyte's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude